logo
SRTS logo
SRTS
Sensus Healthcare

International Expansion And New Verticals Will Diversify Future Revenues

AN
Consensus Narrative from 5 Analysts
Published
28 Sep 24
Updated
26 Mar 25
Share
AnalystConsensusTarget's Fair Value
US$12.00
60.7% undervalued intrinsic discount
26 Mar
US$4.72
Loading
1Y
36.0%
7D
-3.3%

Author's Valuation

US$12.0

60.7% undervalued intrinsic discount

Analyst Price Target Fair Value

Key Takeaways

  • Expanding international sales and entering new verticals indicate potential revenue growth through untapped markets and additional revenue channels.
  • Strong cash position with no debt supports continued investment in R&D and sales, crucial for enhancing future earnings.
  • Dependency on a single large customer presents a concentration risk that could affect future revenues if the relationship changes.

Catalysts

About Sensus Healthcare
    A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.
What are the underlying business or industry changes driving this perspective?
  • The Fair Deal Agreement program is expected to drive significant growth by creating recurring revenue streams from corporate accounts, impacting future revenue positively.
  • Expanding international sales and deepening distributor relationships indicate potential revenue growth in untapped markets for Sensus Healthcare.
  • Diversification into new verticals such as veterinary medicine showcases the potential for opening additional revenue channels.
  • The company's solid cash position, with no debt, allows for continued investment in R&D and sales initiatives, which is crucial for future earnings and profitability.
  • The ongoing enhancement of the product innovation pipeline, including the anticipated resubmission of the TDI 510(k) application, is expected to broaden the product line and boost revenue.

Sensus Healthcare Earnings and Revenue Growth

Sensus Healthcare Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?
  • Analysts are assuming Sensus Healthcare's revenue will grow by 14.5% annually over the next 3 years.
  • Analysts assume that profit margins will shrink from 15.9% today to 14.9% in 3 years time.
  • Analysts expect earnings to reach $9.4 million (and earnings per share of $0.57) by about March 2028, up from $6.6 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $14.4 million in earnings, and the most bearish expecting $4.3 million.
  • In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 25.0x on those 2028 earnings, up from 12.1x today. This future PE is lower than the current PE for the US Medical Equipment industry at 29.7x.
  • Analysts expect the number of shares outstanding to grow by 0.63% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 6.79%, as per the Simply Wall St company report.

Sensus Healthcare Future Earnings Per Share Growth

Sensus Healthcare Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?
  • The decline in gross profit margin from 62.3% to 54.4% in the fourth quarter due to a one-time discount and higher service costs may negatively impact profitability.
  • Increased general and administrative expenses due to higher compensation and professional fees could pressure net profitability.
  • The anticipated decrease in first quarter 2025 sales compared to 2024 could result in fluctuating revenue streams and affect earnings.
  • Dependency on a single large customer, which contributed a substantial number of units, presents a concentration risk that could affect future revenues if the relationship changes.
  • The Fair Deal Agreement's reliance on high patient volumes and the delay in revenue recognition could result in volatility in revenue and profitability if installations face slow ramp-up or underperforming utilization.

Valuation

How have all the factors above been brought together to estimate a fair value?
  • The analysts have a consensus price target of $12.0 for Sensus Healthcare based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $14.0, and the most bearish reporting a price target of just $10.0.
  • In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $62.8 million, earnings will come to $9.4 million, and it would be trading on a PE ratio of 25.0x, assuming you use a discount rate of 6.8%.
  • Given the current share price of $4.88, the analyst price target of $12.0 is 59.3% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

How well do narratives help inform your perspective?

Disclaimer

Warren A.I. is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by Warren A.I. are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that Warren A.I.'s analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

US$13.42
FV
64.8% undervalued intrinsic discount
20.39%
Revenue growth p.a.
6users have liked this narrative
0users have commented on this narrative
43users have followed this narrative
3 months ago author updated this narrative